Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Growth rate is still multiples of the previous year and do not forget the sales team were assembled around June 2019 and would have taken atleast couple months to get their feet under their desk and get to know the product and services they would be selling so that gives around 4 months which is no time. Already produced a fantastic growth of multiples.
1 mill marker has been set for 2019. Even taking 170k off still gives 830k which is still excellent and we will reach profitability H1 2020 I believe. Its important to understand that its not always good you run before you walk. Business’s can’t always do that. No point in acquiring business you can’t deliver - It has to be managed properly with the correct resources keeping a close eye on the balance sheet and. GB has turned around companies To the better so this is a strong hold for me. Figures give or take 170k speak for themselves.
haha, amen!
Me to, James. The big difference is that this MOU is about a sales partnership and having an active sales force in China, must be a huge plus. Of course there is a need for introducing and training the sales force in the product but the Chinese do not sit on there areas when it comes to sales opportunities.
Well i hope they do pay soon! I'm invested in both.
I am confident with GB at the helm here though, barring some catastrophe i think we are in safe hands.
James - forgot the say NFX Chinese money is a milestone payment not a contract so is slightly different.
IMHO this should have been recognised in H1 rev for NFX as CEO has confirmed Chinese intend to pay - revenue is recognised when payment is due not when paid (which is cashflow)
Outlook statement from Dec RNS is below. GB states that he believes average sales are likely to range between £100k to £500k for data as a service to skincare R&D framework multi-year agreements.
So these are not yet in the bag as BELIEVES and LIKELY are included in the sentence.
I agree that £4m 2020 could be quite conservative and GB has stated that he has used a low conversion % to get to his £4m, however, I'm sure GB will be the first to RNS these contracts as and when they drop.
Until a couple of substantial contracts do get over the line I don't think this will re-rate.
Outlook:
Since 2018, the Company has seen average sales grow from £5k for consumable, one-off sales to 2019 average sales of £50k as a service contract. Heading into 2020, Integumen is engaging with multiple top 20 global skin and personal care companies and believes average sales are likely to range between £100k to £500k for data as a service to skincare R&D framework multi-year agreements, providing good visibility of revenue. Therefore, excluding developments that may arise from Integumen entering into the agreement with Parity Group plc, the Company is guiding 2020 revenues of £4m.
Yes but this year included lots of new contracts which havent started paying yet (like the Chinese in nfx) and as such wont be included in last years rev, but will be for next.
I don't for a second believe that 4 mil is exaggerated, if anything it will be conservative.
you don't get from £1m rev to £4m in 12 months without new contracts. GB has assumed a % of those that are in negotiation (some will be warmer than others) will get over the line. Parity deal was signed on same day as 2020 projections so was not included in £4m estimate.
i dont think new contracts are assumed for the forecasts. not even parity is included!
Noticed H1 figures excluded £170k Rhinocloud pre acquisition rev and full year includes this number to get to £1m.
H1 was c£350k and so H2 was really only c£480k as the £170k is added on to this to get to £1m.
2019 H2 growth rate not so wonderful when viewed this way. Maybe that's why the share price is reacting as it is.
Very much a 2020 share for me - good foundation has been set but contracts needed ASAP to hit the targets
Full of it. 1 mill rev for 2019 - Weak. And not forgetting a the MOU with Innocare Group who are already working with some of the top 20 cosmetics companies. Yes full of it. This weakness in sp is due to sell on news. Some have different strategies, some sell on news and some like me hold as we believe in the strong fundamentals. Easy hold
You could well be right, but you have a good man on there now Wadnob, very good researcher,
yeah yeah wickman, keep it up. you'll be gone again before no time.
Still the same James , full of it nothing changed I see.
Oh dear. Hes back
very good RNS, id say my timing was perfect for a change getting back in first thing yesterday, after reading twitter over the weekend just so glad no RNS yesterday, GLA
Super progress.. well done to all the team.
Tic/toc .. buy and hold... enjoy the journey... this man will make your investment very worthwhile